Former Genentech principal scientist and her husband face jail after pleading guilty to stealing corporate information and sharing it with fellow competitors.

Millie Nelson, Editor

July 15, 2021

3 Min Read
Ins & Outs: Ex-Genentech employees plead guilty to sharing trade secrets with competitors
Image: iStock/GOCMEN

A former Genentech principal scientist and her husband face jail after pleading guilty to stealing corporate information and sharing it with fellow competitors. Meanwhile, JHL’s former CEO and COO plead not guilty.

According to the suit, the story goes back to 2009 where Xanthe Lam and her husband, Allen Lam, conspired to commit stealing trade secret information from Genentech and passing the information to Taiwanese firm JHL Biotech (now Eden Biologics).

The husband and wife duo stole confidential property, the suit claims, which included intellectual information about Genentech’s blockbuster cancer drugs Reuters reported.


Image: iStock/GOCMEN

Prosecutors said the information provided helped JHL “cut corners, reduce costs, solve problems, save time, and otherwise accelerate product development timelines.”

The double act also pleaded guilty to other criminal charges. The charges Xanthe Lam pleaded guilty to are as follows:

  • One count of conspiracy to commit computer fraud and abuse,

  • One count of conspiracy to make false statements to a government agency

  • One count making false statements to a government agency

Allen Lam also pleaded guilty to four counts of filing false tax returns and one count of conspiracy to making false statements to a government agency.

The guilty pleas were accepted by William Alsup, US Senior District Judge. Alsup adjourned the case until November 9, 2021.

“Through these cases, our top priority has always been to ensure the return of our trade secrets and confidential and proprietary information and to implement protective measures to ensure this valuable information is no longer used or further disseminated by JHL, these individuals, or other companies,” a spokeswoman for Genentech told us.

“It is also critically important that those who sought to unfairly and illegally profit from our hard work be brought to justice and that the serious consequences of their actions serve as a deterrent to others.”


The Lam’s are not the only people facing criminal charges.

The US Department of Justice (DOJ) unsealed the indictment charging former chief executive officer of JHL Racho Jordanov and ex chief operating officer Rose Lin of conspiracy to commit trade secret theft, wire fraud, international money laundering, and obstruction of justice.

According to court documents, Jordanov and Lin are alleged to have engaged in a “fraudulent scheme” to steal confidential property from Genentech to drive the development and manufacture of biosimilars.

The pair are also accused of defrauding French firm Sanofi out of $101 million by entering a strategic partnership to manufacture and distribute biosimilars in China.

Sanofi allegedly paid JHL $101 million in cash. Jordanov is accused of signing representations and warranties that falsely claim JHL has no knowledge of infringing or misappropriating intellectual property from any third party.

Jordanov and Lin have pleaded not guilty to all charges and are next scheduled to appear in court on August 24, 2021.

The suit follows a settlement between Genentech and Eden Biologics in 2019 resolving all of Genentech’s civil claims.

In a statement regarding the latest charges against the former JHL employees, Eden Biologics said the firm is not subject to prosecution regarding these matters.

“Eden Biologics has been cooperating fully with the Department of Justice in its investigation for several years, and we are pleased that the Department of Justice formally agreed that the company will not face criminal prosecution in this matter,” said Eden Biologics CEO, James Huang.

“These resolutions allow Eden Biologics to continue its relentless focus on delivering high-quality and affordable biosimilar medicines to patients in need and expanding its global CDMO business.”

If you think you have a story that might be of interest to us, please contact [email protected].

About the Author(s)

Millie Nelson

Editor, BioProcess Insider

Journalist covering global biopharmaceutical manufacturing and processing news and host of the Voices of Biotech podcast.

I am currently living and working in London but I grew up in Lincolnshire (UK) and studied in Newcastle (UK).

Got a story? Feel free to email me at [email protected]

You May Also Like